Industry News
NeuroDiscovery makes market debut
Perth-based neurology-focused biotech company NeuroDiscovery (ASX:NDL) listed today on the Australian Stock Exchange at AUD$0.21, one cent above its issue price of $0.20. [ + ]
German Relenza deal shows we're right: Biota
Melbourne-based biopharma Biota Holdings (ASX:BTA) has confirmed that the German government has ordered 1.7 million packs of its flu vaccine Relenza, but CEO Peter Molloy said he still believed that licensee GlaxoSmithKline was not doing enough to promote the drug, . [ + ]
Phylogica and PharmAust sign partnering deal
Phylogica (ASX:PYC) and PharmAust (ASX:PAA) subsidiary Mimotopes have signed a collaborative partnership deal to develop peptide drugs. [ + ]
Polartechnics EGM nixes Opara resolutions
An extraordinary general meeting of Polartechnics (ASX:PLT) shareholders, requisitioned by the company's former interim chairman Richard Opara, has voted against each of the resolutions he put forward. [ + ]
Psivida in talks to acquire US drug delivery company
Trading of shares in Perth-based nano-biotech company Psivida (ASX:PSD) resumed trading today, after the company revealed that it was in negotiations to acquire an as yet unnamed US based specialised drug delivery company. [ + ]
Metabolic pain drug meets trial milestones
Melbourne-based Metabolic Pharmaceuticals (ASX:MBP) has received a go-ahead to progress its painkiller ACV1 to the second part of its phase I clinical trial dosing in humans. [ + ]
Merck exec calls for biotech critical mass
The oft-repeated cliche that Australia 'punches above its weight' in biotechnology is little more than a security blanket, and needs to be replaced with some real muscle, Merck Sharp & Dohme's external licensing coordinator, Graham Macdonald, told a meeting on Friday. [ + ]
Australian scientists awarded once again
Amid tough global competition, with 500 scientists from 62 countries, Australia has confirmed its position as one of the world's pre-eminent biomedical destinations by securing almost 20% of the prestigious worldwide medical research awards announced by the US-based Howard Hughes Medical Institute (HHMI).
[ + ]Banana and mosquito research
Two researchers from Queensland are contributing to a $436 million global plan to improve the health of millions of people in some of the world's poorest countries.
[ + ]Laboratories designed to inspire
The term 'Cathedrals of the Future' has been coined for the world's most impressive biotechnology complexes which are designed to provide a stimulating working environment for the best scientific minds. The road to discovery needs every assistance it can get to facilitate research and attract top researchers.
[ + ]WA forum looks to the future of agbiotech
The Western Australian branch of industry association AusBiotech has held a forum to examine the issues facing agricultural biotechnology in the state, and the challenges that must be faced if it is to move forward. [ + ]
NeuroDiscovery closes IPO
Perth-based neurology-focused biotech company NeuroDiscovery (ASX:NDL) has closed its $1.5 million IPO and completed its acquisition of UK-based NeuroSolutions. [ + ]
EG Capital tips market upswing
In the wake of its annual Australian Biotechnology Expo, held earlier this week in Sydney, EG Capital executive director Alison Coutts is optimistic that the Australian biotech sector is on the way back up. [ + ]
Dental expert wins $50,000 Victoria Prize
Dental scientist Prof Eric Reynolds has won the $50,000 Victoria Prize. [ + ]
Failed Allergan agreement hits Peplin's bottom line
Brisbane-based cancer therapeutic developer Peplin's (ASX:PEP) revenues dropped to AUD$3.4 million in the 2004/05 financial year, down substantially from $6.3 million in the previous year, due to the termination in October 2004 of a collaboration and license agreement with US company Allergan for the company's topical skin cancer drug PEP005. [ + ]
